Barclays’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-315,000
| Closed | -$153M | – | 5688 |
|
|
2025
Q3 | $153M | Buy |
+315,000
| New | +$147M | 0.03% | 368 |
|
|
2025
Q1 | – | Sell |
-39,600
| Closed | -$20.6M | – | 5551 |
|
|
2024
Q4 | $20.6M | Buy |
39,600
+29,100
| +277% | +$16M | 0.01% | 1108 |
|
|
2024
Q3 | $6.49M | Sell |
10,500
-32,500
| -76% | -$19.2M | ﹤0.01% | 1837 |
|
|
2024
Q2 | $23.8M | Buy |
43,000
+30,100
| +233% | +$17.2M | 0.01% | 879 |
|
|
2024
Q1 | $7.5M | Sell |
12,900
-200
| -2% | -$112K | ﹤0.01% | 1584 |
|
|
2023
Q4 | $6.95M | Buy |
+13,100
| New | +$6.34M | ﹤0.01% | 1818 |
|
|
2023
Q3 | – | Sell |
-58,200
| Closed | -$30.4M | – | 4709 |
|
|
2023
Q2 | $30.4M | Buy |
+58,200
| New | +$31.4M | 0.02% | 598 |
|
|
2023
Q1 | – | Sell |
-400
| Closed | -$220K | – | 5348 |
|
|
2022
Q4 | $220K | Hold |
400
| – | – | ﹤0.01% | 3784 |
|
|
2022
Q3 | $202K | Buy |
+400
| New | +$224K | ﹤0.01% | 3201 |
|
|
2021
Q1 | – | Sell |
-10,200
| Closed | -$4.75M | – | 5183 |
|
|
2020
Q4 | $4.75M | Hold |
10,200
| – | – | ﹤0.01% | 1553 |
|
|
2020
Q3 | $4.5M | Buy |
+10,200
| New | +$4.21M | ﹤0.01% | 1464 |
|
|
2020
Q2 | – | Sell |
-27,900
| Closed | -$7.91M | – | 6224 |
|
|
2020
Q1 | $7.91M | Sell |
27,900
-23,600
| -46% | -$7.44M | 0.01% | 1140 |
|
|
2019
Q4 | $16.7M | Buy |
51,500
+18,700
| +57% | +$5.67M | 0.01% | 1052 |
|
|
2019
Q3 | $9.55M | Sell |
32,800
-13,400
| -29% | -$3.84M | 0.01% | 1314 |
|
|
2019
Q2 | $13.6M | Buy |
46,200
+36,200
| +362% | +$9.97M | 0.01% | 1164 |
|
|
2019
Q1 | $2.74M | Sell |
10,000
-53,900
| -84% | -$13.4M | ﹤0.01% | 2238 |
|
|
2018
Q4 | $14.3M | Sell |
63,900
-11,300
| -15% | -$2.65M | 0.01% | 945 |
|
|
2018
Q3 | $18.4M | Buy |
75,200
+24,300
| +48% | +$5.59M | 0.01% | 902 |
|
|
2018
Q2 | $10.5M | Buy |
50,900
+8,400
| +20% | +$1.78M | 0.01% | 1181 |
|
|
2018
Q1 | $8.78M | Buy |
42,500
+19,900
| +88% | +$4.18M | 0.01% | 1252 |
|
|
2017
Q4 | $4.29M | Buy |
22,600
+7,600
| +51% | +$1.46M | ﹤0.01% | 1787 |
|
|
2017
Q3 | $2.84M | Buy |
15,000
+1,800
| +14% | +$326K | ﹤0.01% | 2012 |
|
|
2017
Q2 | $2.3M | Sell |
13,200
-4,600
| -26% | -$773K | ﹤0.01% | 2115 |
|
|
2017
Q1 | $2.73M | Sell |
17,800
-8,700
| -33% | -$1.33M | ﹤0.01% | 1785 |
|
|
2016
Q4 | $3.74M | Sell |
26,500
-81,100
| -75% | -$12M | ﹤0.01% | 1590 |
|
|
2016
Q3 | $17.1M | Buy |
107,600
+3,600
| +3% | +$555K | 0.02% | 613 |
|
|
2016
Q2 | $15.4M | Buy |
104,000
+87,200
| +519% | +$12.9M | 0.02% | 632 |
|
|
2016
Q1 | $2.37M | Sell |
16,800
-71,400
| -81% | -$9.57M | ﹤0.01% | 1770 |
|
|
2015
Q4 | $12.4M | Sell |
88,200
-14,700
| -14% | -$1.96M | 0.02% | 784 |
|
|
2015
Q3 | $12.6M | Buy |
102,900
+27,800
| +37% | +$3.62M | 0.02% | 818 |
|
|
2015
Q2 | $9.69M | Sell |
75,100
-8,400
| -10% | -$1.1M | 0.01% | 1049 |
|
|
2015
Q1 | $11.2M | Buy |
83,500
+9,600
| +13% | +$1.24M | 0.01% | 1005 |
|
|
2014
Q4 | $9.24M | Sell |
73,900
-30,600
| -29% | -$3.72M | 0.01% | 1240 |
|
|
2014
Q3 | $12.6M | Buy |
104,500
+19,000
| +22% | +$2.31M | 0.01% | 1009 |
|
|
2014
Q2 | $10.1M | Buy |
85,500
+6,500
| +8% | +$765K | 0.01% | 1147 |
|
|
2014
Q1 | $9.48M | Buy |
79,000
+72,300
| +1,079% | +$8.6M | 0.01% | 1182 |
|
|
2013
Q4 | $744K | Sell |
6,700
-29,200
| -81% | -$2.9M | ﹤0.01% | 3707 |
|
|
2013
Q3 | $3.3M | Sell |
35,900
-156,500
| -81% | -$14.2M | ﹤0.01% | 2068 |
|
|
2013
Q2 | $16.3M | Buy |
+192,400
| New | +$16M | 0.02% | 753 |
|
Other funds holding TMO
VCM
Barclays's TMO Position: Q1 2026 in Review
Barclays increased its Thermo Fisher Scientific (TMO) stake by 10% in Q1 2026, buying an estimated $94.6M and bringing the position to 1,844,083 shares worth $906M. The position accounts for 0.22% of the portfolio, ranked #65.
Barclays first reported a position in TMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.06B in Q3 2024. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.
- Barclays held 1,844,083 shares of Thermo Fisher Scientific worth $906M as of Q1 2026.
- Barclays bought 174,349 Thermo Fisher Scientific shares in Q1 2026, an estimated $94.6M.
- Thermo Fisher Scientific made up 0.22% of Barclays's portfolio in Q1 2026, its #65 holding.
- Barclays first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 52 quarters since.
- Barclays's Thermo Fisher Scientific position peaked at $1.06B in Q3 2024.
- 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.